Drugs / IGIV3I Grifols
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00699140 | Feb 2008 → Dec 2013 | autoimmune thrombocytopenic purpura | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGIV3I Grifols | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00699140 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin Intravenous (Human)” NCT00699140 ↗ |
| Route | Intravenous | “given intravenously over either 2 days or 5 days in divided doses” NCT00699140 ↗ |